Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified

HIGHLIGHTS

• who: Kaiqi Liu from the State Key Laboratory of, National Clinical Medical College, Tianjin, China have published the research: Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified, in the Journal: (JOURNAL)

SUMMARY

CR before allo-HSCT. Other salvage therapies are needed to improve the CR before allo-HSCT. Venetoclax, a potent oral inhibitor of BCL-2, has demonstrated clinical efficacy in various hematological malignancies. The authors evaluated the therapeutic effect of venetoclax-based treatment in six R/R ALAL-NOS patients . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.